Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMJQ4L7)

Drug Name
N-oleoylethanolamide Drug Info
Synonyms
n-Oleoylethanolamine; n-oleoylethanolamine; oleoylethanolamide; N-(2-Hydroxyethyl)oleamide; 111-58-0; Oleylethanolamide; N-oleoyl ethanolamine; Oleamide MEA; Oleoyl monoethanolamide; Oleoyl Ethanolamide; N-(2-Hydroxyethyl)-9-octadecenamide; N-(Hydroxyethyl)oleamide; UNII-1HI5J9N8E6; (Z)-N-(2-hydroxyethyl)octadec-9-enamide; Oleic acid ethanolamide; N-(9Z-octadecenoyl)-ethanolamine; EINECS 203-884-8; OEA; MLS002153155; CHEMBL280065; 1HI5J9N8E6; (9Z)-N-(2-hydroxyethyl)octadec-9-enamide; Monoethanolamine oleic acid amide; CHEBI:71466; N-oleoylethanolamine; oleylethanolamide; NOE; OLEOYLETHANOLAMIDE
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
5283454
ChEBI ID
CHEBI:71466
CAS Number
CAS 111-58-0
TTD Drug ID
DMJQ4L7

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Cannabinoid receptor 1 (CB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [6]
NABILONE DMVRYT2 Insomnia 7A00-7A0Z Approved [7]
Orlistat DMRJSP8 Obesity 5B81 Approved [8]
SR141716A DMCO5JZ Obesity 5B81 Approved [9]
Tebipenem DMVSX6O Urinary tract infection GC08 Phase 3 [10]
Conatumumab DM2UOSN Colorectal cancer 2B91.Z Phase 2 [11]
GW-42004 DMY3KSU Lipid metabolism disorder 5C52.Z Phase 2 [12]
SR-147778 DMNAECP Obesity 5B81 Phase 2 [13]
Nimacimab DM21Z68 Diabetic nephropathy GB61.Z Phase 2 [14]
AEF0117 DMQ1GH4 Marijuana use disorder 6C41 Phase 2 [15]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Peroxisome proliferator-activated receptor alpha (PPARA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Lobeglitazone DMHY3IP Type-2 diabetes 5A11 Approved [16]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [17]
Bezafibrate DMZDCS0 Hypercholesterolaemia 5C80.0 Approved [18]
Ciprofibrate DMGC5DB Hyperlipoproteinemia 5C80 Approved [17]
Pemafibrate DMD1VZL Hyperlipidemia 5C80.Z Approved [19]
MURAGLITAZAR DMG3NFZ N. A. N. A. Phase 3 [20]
Ragaglitazar DMFSHEM Type-1 diabetes 5A10 Phase 3 [21]
CS-038 DM67P0F Type-2 diabetes 5A11 Phase 3 [22]
TESAGLITAZAR DMGRBN5 Type-1 diabetes 5A10 Phase 3 [23]
GFT-505 DM7ZOAE Non-alcoholic steatohepatitis DB92.1 Phase 3 [24]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting G-protein coupled receptor 55 (GPR55)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [2]
BIO-017 DMYHK3Y Angelman syndrome LD90.0 Phase 1 [25]
[3H]CP55940 DMU7FC5 Discovery agent N.A. Investigative [2]
lysophosphatidylinositol DMETM3R Discovery agent N.A. Investigative [3]
O-1602 DM9VISB Discovery agent N.A. Investigative [26]
abnormal cannabidiol DMV6DAO Discovery agent N.A. Investigative [2]
O-arachidonoyl ethanolamine DML0P72 Discovery agent N.A. Investigative [2]
CID1172084 DMK6YOP Discovery agent N.A. Investigative [27]
CID16020046 DMLWZRT Discovery agent N.A. Investigative [28]
2-arachidonyl glyceryl ether DM2H8TV Discovery agent N.A. Investigative [2]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting Glucose-dependent insulinotropic receptor (GPR119)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Guanfacine extended release DMB1CZ8 Attention deficit hyperactivity disorder 6A05.Z Approved [29]
DS-8500 DMUXIRM Diabetic complication 5A2Y Phase 2 [30]
SAR-260093 DMBJU2G Type-2 diabetes 5A11 Phase 2 [31]
GSK1292263 DMDMXKQ Gastric adenocarcinoma 2B72 Phase 2 [32]
BMS-903452 DM7JW0B Type-2 diabetes 5A11 Phase 1 [33]
APD-597 DM36FOG Type-2 diabetes 5A11 Phase 1 [34]
DA-1241 DMPJA64 Type 2 diabetes 5A11 Phase 1 [35]
APD668 DMN8R2U Type-2 diabetes 5A11 Discontinued in Phase 1 [36]
PSN821 DMGEWUS Type-2 diabetes 5A11 Terminated [37]
lysophosphatidylinositol DMETM3R Discovery agent N.A. Investigative [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By ATP-dependent translocase ABCB1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Flupentixol DM0DJ9O Schizophrenia 6A20 Approved [39]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [40]
Crizotinib DM4F29C Non-small-cell lung cancer 2C25.Y Approved [41]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [42]
Cepharanthine DM9Y5JB N. A. N. A. Approved [43]
Itraconazole DMCR1MV Aspergillosis 1F20 Approved [44]
Clozapine DMFC71L Schizophrenia 6A20 Approved [45]
Midostaurin DMI6E0R Acute myeloid leukaemia 2A60 Approved [46]
Trifluoperazine DMKBYWI Anxiety Approved [47]
Olanzapine DMPFN6Y Bipolar depression Approved [45]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cannabinoid receptor 1 (CB1) TT6OEDT CNR1_HUMAN Inhibitor [1]
G-protein coupled receptor 55 (GPR55) TTNET8J GPR55_HUMAN Agonist [2]
Glucose-dependent insulinotropic receptor (GPR119) TT7QNVC GP119_HUMAN Agonist [3]
Peroxisome proliferator-activated receptor alpha (PPARA) TTJ584C PPARA_HUMAN Agonist [4]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Regulation of Drug Effects [5]

References

1 Conformationally constrained fatty acid ethanolamides as cannabinoid and vanilloid receptor probes. J Med Chem. 2009 May 14;52(9):3001-9.
2 The orphan receptor GPR55 is a novel cannabinoid receptor. Br J Pharmacol. 2007 Dec;152(7):1092-101.
3 Screening beta-arrestin recruitment for the identification of natural ligands for orphan G-protein-coupled receptors. J Biomol Screen. 2013 Jun;18(5):599-609.
4 Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology. 2005 Jun;48(8):1147-53.
5 Intestinal P-glycoprotein exports endocannabinoids to prevent inflammation and maintain homeostasis. J Clin Invest. 2018 Aug 31;128(9):4044-4056. doi: 10.1172/JCI96817. Epub 2018 Aug 13.
6 Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol. 2009 Feb;156(3):397-411.
7 Novel 1',1'-chain substituted hexahydrocannabinols: 9-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid r... J Med Chem. 2010 Oct 14;53(19):6996-7010.
8 Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism. J Med Chem. 2008 Nov 13;51(21):6970-9.
9 Anti-obesity drugs. Expert Opin Pharmacother. 2008 Jun;9(8):1339-50.
10 Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
11 Clinical pipeline report, company report or official report of AstraZeneca (2009).
12 Company report (Gwpharm)
13 Surinabant, a selective cannabinoid receptor type 1 antagonist, inhibits 9-tetrahydrocannabinol-induced central nervous system and heart rate effects in humans.Br J Clin Pharmacol.2013 Jul;76(1):65-77.
14 Clinical pipeline report, company report or official report of Bird Rock Bio.
15 Clinical pipeline report, company report or official report of Affimed Therapeutics.
16 Tolerability and pharmacokinetics of lobeglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, after a single oral administration in healthy female subjects. Clin Drug Investig. 2014 Jul;34(7):467-74.
17 Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem. 2000 Jun 2;275(22):16638-42.
18 Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in... Mol Pharmacol. 2009 Apr;75(4):782-92.
19 Pemafibrate: First Global Approval. Drugs. 2017 Oct;77(16):1805-1810.
20 Muraglitazar, a dual (alpha/gamma) PPAR activator: a randomized, double-blind, placebo-controlled, 24-week monotherapy trial in adult patients with... Clin Ther. 2005 Aug;27(8):1181-95.
21 Ragaglitazar: the pharmacokinetics, pharmacodynamics, and tolerability of a novel dual PPAR alpha and gamma agonist in healthy subjects and patients with type 2 diabetes. J Clin Pharmacol. 2003 Nov;43(11):1244-56.
22 Determination of chiglitazar, a dual alpha/gamma peroxisome proliferator-activated receptor (PPAR) agonist, in human plasma by liquid chromatograph... Pharmazie. 2007 Nov;62(11):825-9.
23 Tesaglitazar, a dual PPAR-/ agonist, hamster carcinogenicity, investigative animal and clinical studies.Toxicol Pathol.2012;40(1):18-32.
24 Dual peroxisome proliferator-activated receptor / agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects.Diabetes Care.2013 Oct;36(10):2923-30.
25 Clinical pipeline report, company report or official report of Biom Therapeutics
26 International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB and CB Pharmacol Rev. 2010 Dec;62(4):588-631.
27 Identification of the GPR55 agonist binding site using a novel set of high-potency GPR55 selective ligands. Biochemistry. 2011 Jun 28;50(25):5633-47.
28 A selective antagonist reveals a potential role of G protein-coupled receptor 55 in platelet and endothelial cell function. J Pharmacol Exp Ther. 2013 Jul;346(1):54-66.
29 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 126).
30 Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.
31 GPR119 agonists for the treatment of type 2 diabetes. Expert Opin Ther Pat. 2009 Oct;19(10):1339-59.
32 Gut hormone pharmacology of a novel GPR119 agonist (GSK1292263), metformin, and sitagliptin in type 2 diabetes mellitus: results from two randomized studies.PLoS One.2014 Apr 3;9(4):e92494.
33 Discovery of 5-chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an antidiabetic clinical candidate targeting GPR119. J MedChem. 2014 Sep 25;57(18):7499-508.
34 Discovery of a second generation agonist of the orphan G-protein coupled receptor GPR119 with an improved profile. Bioorg Med Chem Lett. 2012 Feb 15;22(4):1750-5.
35 ClinicalTrials.gov (NCT03646721) A Study to Evaluate the Safety, Tolerability, PK and PD of DA-1241 in Healthy Male Subjects and Subjects With T2DM. U.S. National Institutes of Health.
36 Announces Initiation of Phase 1 Clinical Trial of Arena Type 2 Diabetes Drug Candidate in Collaboration With Ortho-McNeil. Arena Pharmaceuticals, Inc. FEBRUARY 07, 2006.
37 Clinical pipeline report, company report or official report of Astellas Pharma (2011).
38 Lysophosphatidylcholine enhances glucose-dependent insulin secretion via an orphan G-protein-coupled receptor. Biochem Biophys Res Commun. 2005 Jan 28;326(4):744-51.
39 Characteristics of P388/VMDRC.04, a simple, sensitive model for studying P-glycoprotein antagonists. Cancer Res. 1994 Feb 1;54(3):730-7.
40 Michaelis-Menten kinetic analysis of drugs of abuse to estimate their affinity to human P-glycoprotein. Toxicol Lett. 2013 Feb 27;217(2):137-42. doi: 10.1016/j.toxlet.2012.12.012. Epub 2012 Dec 27.
41 Editor's Highlight: PlacentalDisposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. Toxicol Sci. 2017 Jun 1;157(2):500-509. doi: 10.1093/toxsci/kfx063.
42 Functional evaluation of polymorphisms in the human ABCB1 gene and the impact on clinical responses of antiepileptic drugs. Pharmacogenet Genomics. 2008 May;18(5):390-402. doi: 10.1097/FPC.0b013e3282f85e36.
43 Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci. 2005 Jun;96(6):372-6. doi: 10.1111/j.1349-7006.2005.00057.x.
44 Clinical pharmacokinetic monitoring of itraconazole is warranted in only a subset of patients. Ther Drug Monit. 2005 Jun;27(3):322-33. doi: 10.1097/01.ftd.0000150135.22645.ea.
45 Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein. Psychopharmacology (Berl). 2006 Sep;187(4):415-23. doi: 10.1007/s00213-006-0437-9. Epub 2006 Jun 30.
46 Actions of the selective protein kinase C inhibitor PKC412 on B-chronic lymphocytic leukemia cells in vitro. Haematologica. 2002 Feb;87(2):167-76.
47 Characterization of the ATPase activity of the Mr 170,000 to 180,000 membrane glycoprotein (P-glycoprotein) associated with multidrug resistance in K562/ADM cells. Cancer Res. 1988 Sep 1;48(17):4926-32.